{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:29:27Z","timestamp":1793852967860,"version":"4.6.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"am","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jaapos.2022.11.020","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T15:16:00Z","timestamp":1674141360000},"page":"10.e1-10.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity"],"prefix":"10.1016","volume":"27","author":[{"given":"David K.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amra","family":"Hercinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon F.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit R.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael X.","family":"Repka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuokai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy W.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Kraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2022.11.020_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Pediatric Eye Disease Investigator Group (PEDIG). Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"Pediatric Eye Disease Investigator Group. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.11.020_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamaophthalmol.2019.4488","article-title":"Writing Committee for Pediatric Eye Disease Investigator Group. Secondary 12-month ocular outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity","volume":"138","author":"Crouch","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Pediatric Eye Disease Investigator Group. Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.11.020_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/0734282906297199","article-title":"Test Review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development \u2013 Third Edition. San Antonio, TX: Harcourt Assessment","volume":"25","author":"Albers","year":"2007","journal-title":"J\u00a0Psychoeduc Assess"},{"key":"10.1016\/j.jaapos.2022.11.020_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jaapos.2022.11.020_bib9","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-3091","article-title":"Neurodevelopmental impairment among extremely preterm infants in the neonatal research network","volume":"141","author":"Adams-Chapman","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2022.11.020_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/OPX.0b013e318196bd35","article-title":"Teller II and Cardiff Acuity testing in a school-age deafblind population","volume":"86","author":"Johnson","year":"2009","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jaapos.2022.11.020_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"key":"10.1016\/j.jaapos.2022.11.020_bib12","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2022.11.020_bib13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2022.11.020_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2022.0030","article-title":"Hartnett ME, Wallace DK, et al. Plasma levels of bevacizumab and vascular endothelial growth factor after low-dose bevacizumab treatment for retinopathy of prematurity in infants","volume":"140","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.11.020_bib17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ophtha.2005.03.025","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity","volume":"112","author":"Davitt","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.11.020_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejpn.2013.11.011","article-title":"Validity of US norms for the Bayley Scales of Infant Development-III in Malawian children","volume":"18","author":"Cromwell","year":"2014","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853123000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853123000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:25:41Z","timestamp":1761078341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853123000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1091853123000113"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2022.11.020","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2022.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}